AUTHOR=Schepetkin Igor A. , Kovrizhina Anastasia R. , Stankevich Ksenia S. , Khlebnikov Andrei I. , Kirpotina Liliya N. , Quinn Mark T. , Cook Matthew J. 

TITLE=Design, synthesis and biological evaluation of novel O-substituted tryptanthrin oxime derivatives as c-Jun N-terminal kinase inhibitors

JOURNAL=Frontiers in Pharmacology

VOLUME=13

YEAR=2022

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.958687

DOI=10.3389/fphar.2022.958687

ISSN=1663-9812

ABSTRACT=<p>The c-Jun <italic>N</italic>-terminal kinase (JNK) family includes three proteins (JNK1-3) that regulate many physiological processes, including inflammatory responses, morphogenesis, cell proliferation, differentiation, survival, and cell death. Therefore, JNK represents an attractive target for therapeutic intervention. Herein, a panel of novel tryptanthrin oxime analogs were synthesized and evaluated for JNK1-3 binding (K<sub>d</sub>) and inhibition of cellular inflammatory responses (IC<sub>50</sub>). Several compounds exhibited submicromolar JNK binding affinity, with the most potent inhibitor being 6-(acetoxyimino)indolo[2,1-<italic>b</italic>]quinazolin-12(6<italic>H</italic>)-one (<bold>1j</bold>), which demonstrated high JNK1-3 binding affinity (K<sub>d</sub> = 340, 490, and 180 nM for JNK1, JNK2, and JNK3, respectively) and inhibited lipopolysaccharide (LPS)-induced nuclear factor-κB/activating protein 1 (NF-κB/AP-1) transcription activity in THP-1Blue cells and interleukin-6 (IL-6) production in MonoMac-6 monocytic cells (IC<sub>50</sub> = 0.8 and 1.7 μM, respectively). Compound <bold>1j</bold> also inhibited LPS-induced production of several other proinflammatory cytokines, including IL-1α, IL-1β, granulocyte-macrophage colony-stimulating factor (GM-CSF), monocyte chemoattractant protein-1 (MCP-1), and tumor necrosis factor (TNF) in MonoMac-6 cells. Likewise, <bold>1j</bold> inhibited LPS-induced c-Jun phosphorylation in MonoMac-6 cells, directly confirming JNK inhibition. Molecular modeling suggested modes of binding interaction of selected compounds in the JNK3 catalytic site that were in agreement with the experimental JNK3 binding data. Our results demonstrate the potential for developing anti-inflammatory drugs based on these nitrogen-containing heterocyclic systems.</p>